The Pathologist / Issues / 2026 / February / Breaking the Biomarker Bottlenecks Part 1 / Notecards
Oncology Precision medicine Bioinformatics Companion diagnostics Omics Technology and innovation Insights Opinion and Personal Narratives Molecular Pathology Voices in the Community

Breaking the Biomarker Bottlenecks: Part 1

When pharmaceutical and diagnostic companies collaborate, precision medicine reaches patients faster, say these industry leaders

02/13/2026 Interview 8 min read

Share

0

  1. Companion diagnostics enhance therapy effectiveness.

  2. Infrastructure and regulatory challenges hinder their widespread use.

  3. Pharmaceutical–diagnostics industry partnerships are essential for accelerating companion diagnostics development.

  4. AI-enhanced tools can help democratize healthcare access, especially in underserved areas.

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Recommended